Intervet/Merck Animal Health
FELINE RHINOTRACHEITIS-CALICI-PANLEUKOPENIA-CHLAMYDIA PSITTACI VACCINE Modified Live Virus and Chlamydia
FOR ANIMAL USE ONLY
IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.
THIMEROSAL FREE
INDICATIONS: This product has been shown to be effective for vaccination of healthy cats 9 weeks of age or older against feline rhinotracheitis, calici, panleukopenia viruses and Chlamydia psittaci. Duration of Immunity has not been established. To review efficacy and safety data, go to productdata.aphis.usda.gov.
DOSAGE AND ADMINISTRATION: Transfer contents of the diluent vial to the NobivacĀ® Feline 1-HCPCh vial aseptically. Mix gently until dissolved.
Two doses are required for primary immunization.
Initial vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly at 9 weeks of age or older.
Second vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.
The presence of maternal antibodies is known to interfere with the development of active immunity in cats and additional boosters will be required in most young animals. Historically, annual revaccination has been recommended for this product. The need for this booster has not been established. For more information on revaccination frequency, in general or in the face of maternal antibody, consult your veterinarian or the manufacturer.
PRECAUTIONS:
⢠Store at 2° - 8°C (35°-46°F).
⢠Do not freeze.
⢠Use new, non-chemically sterilized needles and syringes.
⢠Do not mix with other products, except as specified on the label.
⢠Inactivate unused contents before disposal.
⢠In case of human exposure, contact a physician.
WARNINGS:
⢠Contains gentamicin as a preservative.
⢠Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas.
⢠Do not vaccinate pregnant cats.
⢠The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.